Market Place
Sourcing Support
First Patient Enrolled in STK11 Lung Cancer Phase I at Moffitt
24 Sep 2024 //
GLOBENEWSWIRE
Panbela Issued US, Canada Patent For Eflornithine-Sulindac Combo
06 May 2024 //
GLOBENEWSWIRE
Eflornithine (DFMO) Abstract Accepted for DDW Oral Presentation
30 Apr 2024 //
GLOBENEWSWIRE
Norgine Submits MAA For Eflornithine In High-Risk Neuroblastoma
15 Apr 2024 //
PR NEWSWIRE
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine
18 Dec 2023 //
GLOBENEWSWIRE
Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting
01 Jun 2023 //
GLOBENEWSWIRE
Orbus Enters Agreement to Treatment of Rare Pediatric Syndrome with Eflornithine
10 Jan 2023 //
GLOBENEWSWIRE
Orbus’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment
19 Jan 2022 //
GLOBENEWSWIRE
Orbus Therapeutics Receives U.S. Patent for Eflornithine Formulations
23 Dec 2020 //
GLOBENEWSWIRE
Orbus Therapeutics Receives U.S. Patent for Eflornithine Formulations
23 Dec 2020 //
GLOBENEWSWIRE
Cancer Prevention Pharmaceuticals Publishes of Landmark Phase 3 Trial
11 Sep 2020 //
BUSINESS WIRE
STELLAR clinical trial of eflornithine to enrol brain tumour patients
04 Feb 2020 //
CLINICALTRIAL SARINA
Bay Area Startup Orbus Nabs $32.5 Million Series A
19 Aug 2015 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.